SimBioSys® is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, the company is focused on the development of scientific tools to facilitate the drug discovery process. It retains a constant focus on the innovation of algorithms to provide improved throughput and accuracy in the fields of flexible docking, virtual screening and de-novo structure design. SimBioSys is also a pioneer in the field of computer-aided retrosynthetic analysis where it supports chemists through the challenges of organic synthesis. With attention to detail, ease-of-use and improved productivity, SimBioSys has built a strong reputation of delivering state-of-the-art scientific solutions to biotechnology and pharmaceutical companies.
SimBioSys Inc. was incorporated in 1996 as a side venture fom the
Institute for Computer Appliactions in Molecular Sciences (ICAMS) at
the University of Leeds, UK.
Since becoming incorporated, the first 4 years were devoted to the
development of technology infrastructure MoDeST (Molecular Design Software Toolkit). The next years were
focused on application development and today SimBioSys is
ready to market new products such as eHiTS, LASSO, ARChem etc. all developed on its molecular modelling platform: MoDeST
SimBioSys develops 3-dimensional molecular modelling software for the
pharmaceutical drug discovery industry.
The products and services are developed with the following goals in
- acceleration of the drug discovery process
- increasing the speed and accuracy of drug R&D
- increasing the quality of research decisions
The Company's Vision
SimBioSys envisions being a leader in providing the highest quality and
performance interactive visual design software for the biomolecular
The company's aim revolves around its mission statement: Reality3 - to be realistic in all three
- fully interactive real-time
- using realistic
- packaged together to provide the most realistic visualization possible.